<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147415</url>
  </required_header>
  <id_info>
    <org_study_id>TM008</org_study_id>
    <nct_id>NCT05147415</nct_id>
  </id_info>
  <brief_title>Phase 2b Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)</brief_title>
  <official_title>A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saniona</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saniona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2b, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to&#xD;
      evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 16 years&#xD;
      of age or older, with HO&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight (%)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Percentage change in body weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight loss</measure>
    <time_frame>Week 36</time_frame>
    <description>Proportion of subjects who meet pre-specified thresholds for body weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kg)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Change in body weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference (cm)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Change in waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Change in BMI</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Hypothalamic Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated Tesomet dose from the double-blind period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tesomet Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tesomet Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tesomet High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesomet</intervention_name>
    <description>Fixed-dose combination</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tesomet High Dose</arm_group_label>
    <arm_group_label>Tesomet Low Dose</arm_group_label>
    <arm_group_label>Tesomet Medium Dose</arm_group_label>
    <other_name>tesofensine</other_name>
    <other_name>metoprolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subject and, if applicable, their parent or legal guardian must be willing to provide&#xD;
             informed consent&#xD;
&#xD;
          -  Diagnosis of HO secondary to damage to the hypothalamus&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
          -  Female subjects of childbearing potential and male subjects must be willing to use a&#xD;
             highly effective form of birth control during the study&#xD;
&#xD;
          -  At least 6 months since completion of therapy (chemotherapy, surgery, or radiation&#xD;
             with resulting injury to the hypothalamus and/or the pituitary) with stable disease&#xD;
             and lack of recurrence&#xD;
&#xD;
          -  BMI 30.0 to 60.0 kg/mÂ², inclusive&#xD;
&#xD;
          -  Documented stable body weight (gain/loss &lt;10%) for at least 90 days prior to Screening&#xD;
&#xD;
          -  Stable and well-managed pituitary replacement (eg, glucocorticoid, thyroid hormone,&#xD;
             estrogen/progestin or testosterone, desmopressin, or growth hormone) for &gt;2 months&#xD;
             prior to Screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Sitting BP that meets the following criteria after 5 minutes of rest at Screening:&#xD;
&#xD;
               1. Systolic BP &gt;145 mmHg or &lt;100 mmHg; or&#xD;
&#xD;
               2. Diastolic BP &gt;95 mmHg or &lt;70 mmHg&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Active clinical symptoms of delusions, hallucinations, major depressive disorder,&#xD;
             hypomania, or suicidality within 90 days prior to Screening, as defined by the&#xD;
             Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)&#xD;
&#xD;
          -  Uncontrolled endocrine disorders (eg, Cushing syndrome, Addison's, hypothyroidism,&#xD;
             hyperthyroidism)&#xD;
&#xD;
          -  History of bulimia or anorexia nervosa&#xD;
&#xD;
          -  Use of prohibited medications, including current use of selective serotonin reuptake&#xD;
             inhibitors / serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Guillaume, MS</last_name>
    <role>Study Director</role>
    <affiliation>Saniona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alec Gasperian, MS</last_name>
    <phone>1 (323) 207-6751</phone>
    <email>alec@trialtechmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Boak, BSN</last_name>
      <phone>517-364-5733</phone>
      <email>jennifer.boak@sparrow.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Sponsor will consider requests from qualified researchers for access to TM008 study materials</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Following completion of Tesomet clinical development</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

